Background : Bendamustine, a bifunctional alkylating agent with anticipated purin-like properties is active in metastatic breast cancer (MBC) patients.

苯达莫司汀，具有化剂和嘌呤类似的双相功能可以在转移性乳腺（MBC）中发挥作。

Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.

依托泊苷化剂的治疗应该每年接受全血细胞计数检查，以监测骨髓发育不良继发性白血病的发生迹象。